the Belfast unit, as it is known to be the only unit with 80%o of the patients transplanted alive with functioning kidneys two years later.2 The European average is around 50 per cent,3 the United Kingdom median is 38 per cent4 and the least successful United Kingdom units had a success rate of only 15 per cent.' The benefits to individual patients, and the financial savings for health services resulting from all units achieving an 80%o success rate would be considerable.
The reason for the successes in Belfast is a major point of discussion when nephrologists and transplant surgeons meet. It is accepted that the mortality rate in a series of transplant patients will vary dependant on case selection. Those who transplant "high-risk" patients, for example diabetics, are likely to lose more patients but why should some units have less severe rejections or rejection episodes that are more successfully treated? This might also be a function of the patients transplanted, but there is no known way to select a group of patients to achieve results like those reported by Belfast, even in groups of patients who had had previous transfusions which is known to improve results. It is possible that some of the variability between units is the result of chance, but this seems unlikely because results would then be expected to fluctuate widely from year to year, and this is not the case.
The low doses of corticosteroids used by the Belfast group2 contrasts with larger doses by other United Kingdom units, and much larger doses by many United States units.5 The Oxford group did not get comparable results using a similar daily dose,6 but the treatment regimen used in Oxford differed in at least three respects from that in Belfast: (1) a large dose of methyl prednisolone was given routinely 7 days after transplant to anticipate the onset of rejection commonly seen at this time; (2) the dose and duration of corticosteroid therapy given to treat a rejection episode was different, and "bolus" doses of methyl prednisolone were used; (3) a twice daily scheme of administration of prednisolone contrasting with the once daily morning dose in Belfast was used.
The publications from Belfast and Oxford do not comment on the time and frequency of administration, and the information was obtained by personal communication. In most renal transplant units little attention has been given to the time of day of drug administration, or to whether it is given once daily or in divided doses. This criticism also applies to much other therapy in many conditions. Very few publications provide details of timing and frequency of drug treatment, most just state the total amounts given in each 24 hours. Is it possible that the timing of medication is the critical detail that has allowed success in Belfast?
A survey of British transplant units indicated that Belfast were the only group replying who were using a once daily morning dose of prednisolone and azathioprine.18 This timing of corticosteroid therapy reduces adrenopituitary suppression and is widely, although not consistently, adopted in the alternate day regimes used by some in the later stages of renal allograft care. It has not been thought to be important in the immediate post-operative period when most rejections occur, and when adrenopituitary suppression influencing later events could be induced.
Pharmacological immunosuppression is essential for successful renal transplantation except in identical twins. This may have attracted interest away from the immunosuppressive effects of endogenous corticosteroids. Prednisolone and similar exogenous corticosteroids are quickly removed from the blood, having half-lives of only a few hours. In a patient with no natural adrenal activity the blood corticosteroid level will drop to sub-normal levels in the period preceding a dose, unless these are very frequent. This is especially likely to happen in the early morning because patients do not usually take prednisolone medication until breakfast. If there is a functioning adrenopituitary axis there is a progressive rise in cortisol well before breakfast; the normal morning surges of cortisol secretion starting well before waking,' but a functioning adrenopituitary axis is only likely in patients taking more than minimal doses of corticosteroids when they are ingested in the morning7' 8 especially if they have been ingested at this time since the onset of therapy.
In studies on healthy students we demonstrated that immune responses are greater when an antigenic stimulus in sensitised individuals is given at 0700 hours. 9 We have also suggested that the onset of renal allograft rejection in human transplant recipients most frequently has its onset during the night, perhaps especially the latter part of the night.'0 It may be argued that this is the time when the maximal immunosuppressive effect is needed. On treatment regimes which use divided doses morning and evening the exogenous levels will be at their lowest level in the whole 24 hours at this time and there will, due to adrenal suppression from the evening dose, probably be no endogenous cortisol. In regimens with evening dosing alone there may be no endogenous cortisol and little prednisolone in the morning either. If morning only doses of prednisolone only are taken, as with the Belfast patients, there may be an endogenous adrenal response which has not been inhibited by evening doses of corticosteroid, and this may provide an important immunosuppressive effect prior to ingestion of morning tablets.
Animal experiments, recently conducted in our laboratory,"' 12 provide some support for this hypothesis. Rats exposed to methyl prednisolone at different times, which coincide with single doses of the application of an antigenic challenge producing a cell-mediated immune response, show more prolonged suppression of the response at times when the methyl prednisolone should inhibit endogenous corticosteroid production least. Studies recently reported by Leisti and his colleagues '" demonstrated that relapse in steroid-sensitive nephrotic syndrome may be most unlikely in the days of post-corticoid hypoadrenalism after discontinuing therapy. Is it possible that the immunological processes responsible for transplant rejection are inadequately suppressed during the period of iatrogenic hypoadrenalism that occurs daily in those taking evening steroids? Our own retrospective analysis, examining the development of rejection three months or more after successful renal transplantation, suggests that graft damage from this is more likely in those taking evening doses of immunosuppressives only. In those taking divided doses, at least some of the drugs in the morning, greater numbers of grafts remain free of late rejection.'8 We have not kept patients on morning only regimens, but late loss of grafts from rejection is most unusual in the Belfast patients taking morning only doses.
The dose level at which morning doses persist to late evening, and so inhibits endogenous production, is not certain. The large doses used in many transplant units may persist to the evening and patients taking a high dose regime, even if given only in the morning, may have adrenopituitary suppression similar to that occurring in those taking evening doses. It may be that a low total daily dose, 20 mg. daily for the first six months, which is used by the Belfast unit and the fact that it is given as one dose in the morning, usually 1000 hours, are both critical. Their use of "nonenteric" coated tablets, which are more reliably absorbed,'4 and the ingestion of tablets away from breakfast, which could also influence absorption, might also be important.
There has been almost no interest in any clinical specialty about whether there might be a best time of day to give immunosuppressive drugs other than corticosteroids. A few scientists have done many careful experiments which show that cure rates in experimental cancer and leukaemia can be quite different with the same doses of drugs at different times, for example 94 per cent cure rate with the best time contrasting with 44 per cent at the worst times.'5 16 There may also be an important synchronising effect between the timing of glucocorticoid therapy and the effect of other drugs. Cell mitotic rates, which may reflect susceptibility to drug treatment, have marked circadian rhythms."' These can be disrupted when corticosteroid administration does not coincide with the endogenous adrenal rhythmicity,'7 and inappropriately timed dosing of steroids might reduce the effectiveness, or increase the toxicity, or other drugs.
If timing of drug therapy is important statements referring only to the total daily dose of immunosuppression used, standard to nearly all papers on immunosuppression after transplantation, are inappropriately vague. The details about timing included in this paper were only obtained by direct questioning of the units concerned, and did not appear in their published papers. Patients themselves may modify the pattern of drug ingestion, and in addition to the problem of some patients who forget their tablets there are others who, even when instructed about time of ingestion, will take them at other times.
It requires more research, both retrospective studies and prospective comparative investigations, before it will be accepted that the time of administration is even important, let alone critical, to transplant success. While further information is awaited those caring for transplant patients may wonder whether the best rule is not to copy the successful-and give all maintenance immunosuppressives as single morning doses, as in Belfast.
